Guillain–Barré syndrome with associated thrombocytopenia: prompt response to combined corticosteroid and immunoglobulin treatment

1998 ◽  
Vol 8 (1) ◽  
pp. 50-52 ◽  
Author(s):  
Ulisse Corbanese ◽  
Andrea Martinuzzi ◽  
Clemente Possamai ◽  
Giancarlo Romeo ◽  
Giulio Possamai ◽  
...  
Keyword(s):  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Immunoglobulin Treatment ◽  
Guillain Barré ◽  
Prompt Response

scholarly journals Treatment-related fluctuation in Guillain-Barre syndrome

2011 ◽  
Vol 02 (02) ◽  
pp. 168-170 ◽  
Author(s):  
Thirunavukkarasu Thivakaran ◽  
Ranjanie Gamage ◽  
Inuka Kishara Gooneratne
Keyword(s):  
Immune Activation ◽  
Early Treatment ◽  
Disease Onset ◽  
Immunoglobulin Therapy ◽  
Chronic Inflammatory Demyelinating Polyradiculoneuropathy ◽  
Guillain Barre Syndrome ◽  
Disability Scale ◽  
Guillain Barré Syndrome ◽  
Immunoglobulin Treatment ◽  
Guillain Barré

ABSTRACTGuillain-Barre syndrome (GBS) is usually a monophasic illness but relapses occur. A 55-year-old female with hypertension and vitiligo presented with acute inflammatory demyelinating polyradiculoneuropathy. She improved with immunoglobulin treatment started on day 6 of illness, but relapsed on day 14 warranting repeat immunoglobulin therapy. Thereafter recovery was complete. Her relapse was due to treatment-related fluctuation (TRF). TRF is improvement in the GBS disability scale of at least one grade after completion of immunotherapy followed by worsening of the disability scale of at least one grade within the first 2 months after disease onset. Recurrent GBS and chronic inflammatory demyelinating polyradiculoneuropathy were excluded. During the peak of the illness ANA titres were transiently high. The presence of other medical conditions, predominant proximal weakness and the absence of preceding diarrhea are predictors for TRF seen in this patient. Early treatment and evidence of ongoing immune activation have contributed toward TRF.

scholarly journals Guillain-Barré syndrome presenting with COVID-19 infection

2020 ◽  
Vol 13 (9) ◽  
pp. e236978 ◽  
Author(s):  
Nasir Ameer ◽  
Kalyan Mansukhbhai Shekhda ◽  
Ann Cheesman
Keyword(s):  
Neuromuscular Disorder ◽  
Guillain Barre Syndrome ◽  
Limb Weakness ◽  
Neurological Signs ◽  
The Third ◽  
Lower Limb Weakness ◽  
Guillain Barré Syndrome ◽  
Immunoglobulin Treatment ◽  
Systemic Symptoms ◽  
Guillain Barré

A construction worker in his 30s presented three times in 4 days with progressive upper and then lower limb weakness. On the first two occasions he had no systemic symptoms, but on the third presentation he had fever and cough, starting from day 4 of weakness. Examination identified weakness in all four limbs and areflexia, suggesting a peripheral neuromuscular disorder. Investigations were consistent with Guillain-Barré syndrome and additional COVID-19 (SARS-CoV-2) infection. The patient improved after immunoglobulin treatment. At least four cases of Guillain-Barré syndrome have been reported in the literature with concurrent COVID-19 illness in whom respiratory signs appeared a few days after the onset of neurological signs. With the incubation period for COVID-19 respiratory symptoms believed to be up to 14 days, it is possible that neurological symptoms could develop before respiratory and other symptoms. During the current pandemic, presence of concurrent COVID-19 infection needs to be considered in patients presenting with Guillain-Barré syndrome.

Intravenous Immunoglobulin Treatment in Children with Guillain-Barre Syndrome

1995 ◽  
Vol 27 (3) ◽  
pp. 241-243 ◽  
Author(s):  
Nuran Gürses ◽  
Serap Uysal ◽  
Feyzullah Çetinkaya ◽  
Ismail Işek ◽  
Ayhan Gazi Kalayci
Keyword(s):  
Intravenous Immunoglobulin ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Immunoglobulin Treatment ◽  
Guillain Barré

scholarly journals Rescue treatment in patients with poorly responsive Guillain–Barre syndrome

2019 ◽  
Vol 7 ◽  
pp. 205031211984019 ◽  
Author(s):  
Ayman Mahmoud Alboudi ◽  
Pournamy Sarathchandran ◽  
Samar Sameer Geblawi ◽  
Deeb Maxwell Kayed ◽  
Jihad Inshasi ◽  
...  
Keyword(s):  
Plasma Exchange ◽  
Intravenous Immunoglobulin ◽  
Guillain Barre Syndrome ◽  
Line Treatment ◽  
Second Line ◽  
Rescue Treatment ◽  
Significant Difference ◽  
Guillain Barré Syndrome ◽  
Immunoglobulin Treatment ◽  
Guillain Barré

Objectives: To evaluate the effectiveness of rescue treatment (intravenous immunoglobulin or plasma exchange) in patients with Guillain–Barre syndrome who did not respond or deteriorated after the initial management with intravenous immunoglobulin. Methods: We performed a retrospective review of the medical records of patients who responded poorly or did not respond to intravenous immunoglobulin treatment. The disability parameters of those who received second-line treatment with intravenous immunoglobulin or plasma exchange (20 patients) were compared with those who did not receive second-line treatment (19 patients). Results: There was a statistically significant improvement in disability scores at 1 month in the patients who received the rescue treatment (p = 0.033). However, there was no significant difference in the disability scores at 3 and 6 months, or in length of intensive care unit stay. Conclusion: Our study showed that a second course of treatment to carefully selected patients may be beneficial

scholarly journals Guillain-Barré syndrome complicated by takotsubo cardiomyopathy: an under-recognised association

2020 ◽  
Vol 13 (2) ◽  
pp. e233591
Author(s):  
Timothy Jones ◽  
Neelan Umaskanth ◽  
James De Boisanger ◽  
Henry Penn
Keyword(s):  
Takotsubo Cardiomyopathy ◽  
Initial Period ◽  
Acute Chest Pain ◽  
Guillain Barre Syndrome ◽  
Cardiac Recovery ◽  
Coronary Syndrome ◽  
Guillain Barré Syndrome ◽  
Electrocardiographic Changes ◽  
Immunoglobulin Treatment ◽  
Guillain Barré

A 41-year-old woman was admitted with progressive paraesthesia and weakness and was diagnosed with Guillain-Barré syndrome. Following an initial period of recovery with intravenous immunoglobulin treatment, she developed acute chest pain associated with electrocardiographic changes. Investigations excluded acute coronary syndrome and instead confirmed a diagnosis of takotsubo cardiomyopathy, which was treated medically. The patient made an excellent neurological and cardiac recovery. Here we discuss the rarely described association between these two conditions and suggest that patients admitted with Guillain-Barré syndrome may benefit from routine screening with echocardiography.

Sign in / Sign up

Export Citation Format

Share Document